ScoreHaematology
CPSS-Mol in chronic myelomonocytic leukaemia
Clinical-molecular prognosis for CMML combining cytogenetics, four mutations and three clinical parameters.
Updated 31 October 2026
When to use it
Patients with CMML at diagnosis with karyotype and mutation panel, to estimate survival and AML transformation and assess transplant.
What it needs
- Cytogenetic risk (CPSS)
- ASXL1 mutation
- NRAS mutation
- RUNX1 mutation
- SETBP1 mutation
- Bone marrow blasts ≥ 5%
- White cell count ≥ 13 × 10⁹/L
- Red cell transfusion dependence
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Low (0) |
| 1 | Intermediate-1 (1) |
| 2 | Intermediate-2 (2) |
| ≥ 3 | High (≥ 3) |
In the app it also calculates: CPSS-Mol score.
Practical tip
CPSS cytogenetics: low risk = normal or −Y; high = trisomy 8, chromosome 7 abnormalities or complex karyotype; intermediate = all others.
3 more practical tips in the app.
Reference
- Elena C, Gallì A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408-1417.
- Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005-3015.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
